Volume 1, Issue 9


Cover Image

Cover Figure: Paraffin-embedded right heart tissue sections stained with trichrome.
See the article by Asosingh et al.

Join the discussion @ Blood Advances Community Conversations

WASHINGTON, March 28,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

The use of antithymocyte globulin to prevent both acute and chronic graft-versus-host disease as well as promote engraftment has been an area of intense debate. Recent studies add light to this discussion. In this issue’s Point-Counterpoint, Dr. Bacigalupo, and Drs. Kekre and Antin discuss this important topic. We hope you enjoy the discussion and welcome your comments.

Recent evidence has suggested a link between the bone marrow and the heart in the genesis of right ventricle disease and pulmonary hypertension. Asosingh et al, characterize an interesting murine model involving caveolin-1 deficiency where knockout animals develop disease highly similar to pulmonary hypertension with elevated right heart pressure and right ventricle hypertrophy. They find that transplanting caveolin-1 knockout animals with normal bone marrow prevented this disease and the reverse transplant resulted in disease generation, which highlights this interesting and relatively unappreciated interaction between the bone marrow and heart function.

Dendritic cells (DCs) are known to be the primary cells responsible for the initiation of an immune response. DCs express a number of receptors that respond to both endogenous and exogenous ligands and influence both innate and adaptive immunity. In this issue, Lopez Robles and colleagues further characterize the C-type lectin receptor CLEC-1 on human DCs. This receptor was previously identified on rat DCs, where it was demonstrated to downregulate Th17 responses. Their studies demonstrate a role for CLEC-1 as an inhibitory receptor for human DCs that may represent a novel therapeutic target.

Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa. Lombardo and colleagues from the Fred Hutchinson Cancer Research Center, make a Global Advances contribution. They have performed high-throughput sequencing of the B-cell receptor in 51 primary tumors from patients in Ghana and Uganda. Their findings suggest that the disease arises from an abnormal B-cell progenitor and that ongoing mutational processes impact the BL cells.

The plasminogen activation complex is known to be involved in the pathogenesis of inflammatory arthritis in the inbred murine model system. Thornton et al, explore the role of urokinase plasminogen activator and its receptor in mice prone to developing this disease. A role for the receptor in driving the progression of disease when expressed on hematopoietic cells is demonstrated, highlighting this interesting biology.

Featured Visual Abstract

High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis

Katharine A. Lombardo, David G. Coffey, Alicia J. Morales, Christopher S. Carlson, Andrea M. H. Towlerton, Sarah E. Gerdts, Francis K. Nkrumah, Janet Neequaye, Robert J. Biggar, Jackson Orem, Corey Casper, Sam M. Mbulaiteye, Kishor G. Bhatia, Edus H. Warren





Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.